- CEO
- Zi Long Xie
- Full Time Employees
- 36,892
- Sector
- Retail trade
- Industry
- Drugstore chains
- Address
- No. 1 (Xingsha) Kaiyuanxi Road Changsha HU China 410152
- IPO Date
- Apr 23, 2015
- Business
- LBX Pharmacy Chain Joint Stock Company (603883.SS) operates one of China's largest pharmacy retail chains, primarily engaged in the retail and wholesale of pharmaceuticals and health products through an extensive network of stores across mainland China. The company offers proprietary Chinese and Western medicines, traditional Chinese medicine tablets and decoctions, health equipment, health foods, general foods, personal care products, daily necessities, over-the-counter medications, and maternal and infant products; it also provides e-commerce services, Chinese medicine research and development, clinic and medical services, pharmaceutical consulting, information technology consulting, and wholesale distribution to pharmacies, hospitals, and healthcare providers. Operating through retail, wholesale, and other segments including pharmaceutical manufacturing, LBX Pharmacy Chain serves consumers and institutions in 21 provincial markets with over 15,000 stores and approximately 40,000 employees. Founded in 2001 by Zilong Xie and headquartered in Changsha, Hunan province, the company, formerly known as Laobaixing Pharmacy Chain Joint Stock Company, maintains a strong presence in regions including Hunan, Jiangsu, and others while focusing on chronic disease management for conditions such as breast cancer, skin diseases, leukemia, lung cancer, and hemophilia. Recent developments include the completion of acquisitions for stakes in regional pharmacy chains, such as the remaining 35% in Zhenjiang Huakang Pharmacy Chain Co., Ltd. and a 35% stake in Yangzhou Baixinyuan Pharmaceutical Chain Co., Ltd. for CNY210 million, alongside ongoing initiatives like the Torch Project to innovate commercial procurement and enhance profitability, store transformations from transaction-based to relationship-oriented models, and recognitions including a repeat listing in the 2025 China Services Enterprise 500.